LBM-415 is the first member of the peptide deformylase (PDF) inhibitor class. It is being developed for clinical trials as a parenteral and orally bioavailable agent for treatment of community-acquired respiratory tract disease and serious infections caused by antimicrobial-resistant gram-positive cocci. References: Sangshetti JN, Khan FA, Shinde DB. Peptide deformylase: a new target in antibacterial, antimalarial and anticancer drug discovery. Curr Med Chem. 2015;22(2):214-36. Review. PubMed PMID: 25174923.

纯度：≥98%

CAS：478913-91-6